Omnicell, Inc. (NASDAQ:OMCL) Director Mark W. Parrish Sells 12,000 Shares of Stock

Omnicell, Inc. (NASDAQ:OMCL) Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Omnicell Trading Down 2.2 %

NASDAQ:OMCL opened at $45.96 on Friday. The firm has a 50 day moving average of $45.25 and a 200-day moving average of $38.90. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. increased its stake in shares of Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after buying an additional 228,093 shares during the period. Pier Capital LLC bought a new position in Omnicell during the 3rd quarter worth approximately $5,859,000. Federated Hermes Inc. grew its holdings in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the period. Royce & Associates LP acquired a new stake in Omnicell in the third quarter worth $811,000. Finally, Intech Investment Management LLC bought a new position in shares of Omnicell during the third quarter worth $753,000. Institutional investors own 97.70% of the company’s stock.

Analyst Ratings Changes

OMCL has been the subject of several research analyst reports. Bank of America reiterated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. JPMorgan Chase & Co. boosted their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday. Barclays upped their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.